Expert Perspective – Pannash

Category: Expert Perspective

This is our archive page

Nonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)

3 March 2021, by Prof Sven Francque

NAFLD: a year in review

3 March 2021, by G. Bozet, MD

Early NASH development: myosteatosis rather than sarcopenia

3 March 2021, by G. Bozet, MD

Review: outcome of hepatocellular carcinoma in patients with NAFLD

1 March 2021, by G. Bozet, MD

Performance of non-invasive tests for the detection of advanced fibrosis in morbidly obese patients

1 March 2021, by G. Bozet, MD

Metabolic drivers of NAFLD

24 February 2021, by G. Bozet, MD

MAFLD, severe COVID-19 and the gut-liver axis

24 February 2021, by G. Bozet, MD

Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease

22 February 2021, by G. Bozet, MD

Sarcopenia: pathophysiological processes in NAFLD

22 February 2021, by G. Bozet, MD

NAFLD and T2D: A bidirectional relationship

19 February 2021, by G. Bozet, MD